Company Snapshot: Retrophin, Inc.
Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, New York-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin has begun enrollment in a potentially pivotal Phase 2 clinical trial of its lead compound, sparsentan, for FSGS. The Company also intends to reintroduce Syntocinon Nasal Spray (oxytocin) in the U.S. to assist initial postpartum milk ejection and also initiate clinical trials for the drug as a potential treatment for schizophrenia and autism. Retrophin plans to initiate a Phase 1 pharmacokinetic trial of RE-034, an ACTH analog, in the first half of 2014.
- Oct 13 2017 Retrophin to Present New Data for Sparsentan at ASN Kidney Week 2017
- Oct 5 2017 Retrophin Announces Presentation of New Data from Physician-Initiated Treatment with Fosmetpantotenate at the Child Neurology Society’s 26th Annual Meeting
- Sep 11 2017 Retrophin to Present at September Investor Conferences
- Sep 5 2017 Retrophin Announces Cooperative Research and Development Agreement with NCATS and NGLY1.org to Identify Potential Small Molecule Therapeutics for NGLY1 Deficiency